Eralfon 40000 IU 1 ml syringe with needle protection device

Indications

Anemia caused by erythropoietin deficiency in patients with chronic renal failure (CRF).

Pharmacological effect

Recombinant human erythropoietin is a purified glycoprotein.

Special instructions

During treatment, it is necessary to monitor blood pressure weekly and perform a complete blood count (including platelets, hematocrit, ferritin). In the pre- and postoperative period, Hb should be monitored more often if the initial value was less than 140 g/l.

Active ingredient

Epoetin alfa

Composition

1 syringe contains 40,000 IU of recombinant human erythropoietin

Excipients:

sodium chloride – 5.84 mg,

sodium citrate pentasesquihydrate – 5.8 mg or sodium citrate dihydrate – 4.776 mg,

albumin solution (in terms of dry albumin) – 2.5 mg,

citric acid monohydrate – 0.057 mg,

water for d/i – up to 1 ml.

Contraindications

Absolute contraindications have not been identified.

Side Effects

At the beginning of treatment, flu-like symptoms may be observed: dizziness, drowsiness, fever, headache, myalgia, arthralgia.

From the cardiovascular system: dose-dependent increase in blood pressure, worsening of arterial hypertension (most often in patients with chronic renal failure), in some cases – hypertensive crisis, a sharp increase in blood pressure with symptoms of encephalopathy (headache, confusion) and generalized tonic-clonic convulsions.

From the hematopoietic organs: thrombocytosis, in some cases – thrombosis of the shunt or arteriovenous fistula (including patients on hemodialysis with a tendency to arterial hypotension or with an aneurysm, stenosis), aplasia of the erythrocyte lineage.

Allergic reactions: skin rash (mild or moderate), eczema, urticaria, itching, angioedema.

Local reactions: hyperemia, burning, mild or moderate pain at the injection site (more often occur with subcutaneous administration).

From the laboratory parameters: decrease in serum ferritin concentration, with uremia – hyperkalemia, hyperphosphatemia.

Other: complications associated with respiratory failure or decreased blood pressure, immune reactions (induction of antibody formation), exacerbation of porphyria.

Interaction

Reduces the concentration of cyclosporine due to an increase in the degree of its binding to red blood cells (it may be necessary to adjust the dose of cyclosporine).

Overdose

Symptoms: increased side effects.

Storage conditions

At temperatures from 2° to 8°C.

Shelf life

2 years

Manufacturer

PharmFirma Sotex, Russia